Login
Companies $QDEL
$10.19 -$0.02 (0.2%) After hours
QuidelOrtho Corp logo

QuidelOrtho Corp

quidelortho.com

What Do They Do?

Sells diagnostic instruments and tests for laboratory and point-of-care use, and blood-screening products to healthcare facilities, blood and plasma centers, and consumers.

How Do They Make Money?

North America is the largest segment, and revenue comes mainly from product sales paid when products ship or are delivered; customers also pay for service contracts before service is provided.

revenue
SegmentShareRevenue
North America
Sold outright

55%
FY2022: 78%
EMEA
Sold outright

13%
FY2022: 6.3%
China
Sold outright

12%
FY2022: 6.7%
JPAC
Sold outright

11%
Latin America
Sold outright
9.3%

Who Are Their Customers?

Hospitals, laboratories, clinics and blood or plasma centers buy diagnostic products, alongside retailers and individual consumers. Sales are primarily direct in North America and Western Europe, while emerging markets use direct sales and distributors; distributors also help reach smaller North American point-of-care customers.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: no customer at 10% or more of revenue

Do Revenues Turn Into Profits?

No. It lost $1.1B in FY2025.

Operating income, FY2025
−34% of revenue
▲ +53% (Loss) vs FY2024 (−$2B, −70%)
Net income, FY2025
−41% of revenue
▲ +45% (Loss) vs FY2024 (−$2.1B, −74%)
Free cash flow, FY2025
−3% of revenue
▲ +26% (Loss) vs FY2024 (−$112.1M, −4%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 27, 2026
Revenue
▼ −12%
vs $699.9M in Q3 FY2025
Net income
▲ +93% (Loss)
vs −$733M in Q3 FY2025
North America share of revenue vs 54.5% in Q3 FY2025
  • Aug 6, 2026 Cut 2026 revenue and earnings guidance and withdrew free cash flow guidance The updated outlook lowered ranges for revenue, adjusted EBITDA and adjusted diluted earnings per share.
  • Jun 23, 2026 Appointed Micah Young as chief financial officer He succeeded Joseph M. Busky, who had announced his retirement.

U.S. donor screening The older report described donor-screening instruments and tests for blood and plasma screening globally. The latest says QuidelOrtho is winding down its U.S. portfolio while continuing donor screening elsewhere.

Revenue over time
North America EMEA China JPAC Latin America Other
$5B$2.5B$0

Who Do They Compete With?

Competes with Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters, and Wermerson Immuncor

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support